G6PD Deficiency & Drug-Induced Jaundice: Unsafe Medications for Neonates

G6PD Deficiency: India's Hidden Cause of Severe Neonatal Jaundice

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzyme deficiency worldwide, affecting an estimated 400 million people globally. In India, it represents a significant but often underrecognized cause of severe neonatal hyperbilirubinemia, with prevalence rates of 8-15% in males across various populations. The clinical significance lies in the potential for acute hemolytic episodes triggered by oxidative stressors, including commonly used medications, leading to rapid and severe jaundice that can progress to kernicterus if not promptly managed.

For Indian neonatologists, understanding which drugs are unsafe in G6PD-deficient neonates is not merely academic—it is a critical patient safety issue. Many triggers are present in the Indian environment, from naphthalene mothballs in household storage to traditional remedies containing henna and menthol, making parental education as important as clinical management.

Pathophysiology of G6PD-Related Jaundice

The Role of G6PD in Red Blood Cell Protection

G6PD is the rate-limiting enzyme in the pentose phosphate pathway (hexose monophosphate shunt), the sole source of NADPH in red blood cells. NADPH is essential for maintaining glutathione in its reduced state (GSH), which protects RBC membranes, hemoglobin, and other proteins from oxidative damage. Without adequate G6PD activity, RBCs are vulnerable to oxidative stress:

1. Oxidative stressor (drug, infection, food) generates reactive oxygen species (ROS) in RBCs
2. Insufficient NADPH production due to G6PD deficiency prevents GSH regeneration
3. Oxidized hemoglobin denatures and forms Heinz bodies (intracellular precipitates)
4. Heinz body-laden RBCs are trapped and destroyed by splenic macrophages (extravascular hemolysis)
5. Massive release of hemoglobin and heme overwhelms bilirubin conjugation capacity
6. Severe unconjugated hyperbilirubinemia develops rapidly

Why Neonates Are Especially Vulnerable

• Fetal hemoglobin (HbF): More susceptible to oxidative denaturation than adult hemoglobin
• Immature hepatic conjugation: UGT1A1 activity is only 1% of adult levels in the first few days
• Higher baseline hemolysis: Neonatal RBC turnover is physiologically elevated
• Immature antioxidant defenses: Lower catalase, superoxide dismutase, and vitamin E levels

G6PD Deficiency Prevalence in India

Region/Community	Prevalence (%)	Common Variant
Tribal populations (Northeast India)	15-27%	G6PD Mahidol
Parsee community	15-18%	G6PD Mediterranean
Gujarat (Kutch region)	10-15%	G6PD Mediterranean
Rajasthan (Meghwal, Bhil tribes)	10-18%	G6PD Mediterranean
Coastal Maharashtra/Goa	8-12%	G6PD Mediterranean
Southern India (general)	5-8%	G6PD Kerala-Kalyan
Northern India (general)	3-7%	G6PD Mediterranean

The G6PD Mediterranean variant (Class II, severe deficiency) is the most common in India, causing less than 10% residual enzyme activity. This makes Indian G6PD-deficient neonates particularly susceptible to severe hemolytic episodes compared to populations with milder variants (Class III, such as G6PD A- in Africa).

Unsafe Drugs and Substances: Comprehensive List

Definite High-Risk Agents (Contraindicated)

Drug/Substance	Category	Hemolytic Severity	Indian Relevance
Naphthalene (mothballs)	Environmental	Severe	Very high—common in Indian households
Primaquine	Antimalarial	Severe	High—used for P. vivax radical cure
Dapsone	Anti-leprotic/antibiotic	Severe	High—leprosy treatment, maternal use
Methylene blue	Diagnostic/therapeutic	Severe	Moderate—used for methemoglobinemia
Rasburicase	Uricolytic	Severe	Low—rare neonatal use
Nitrofurantoin	Antibiotic	Moderate-severe	High—common maternal UTI treatment
Henna (mehndi)	Traditional cosmetic	Moderate	Very high—cultural practice

Moderate-Risk Agents (Use with Caution)

• Sulfonamides: Cotrimoxazole (commonly prescribed in Indian hospitals)
• Chloramphenicol: Still used in some Indian government hospital NICUs
• Aspirin: Anti-platelet doses; standard doses can trigger hemolysis
• Menthol/camphor: Common in traditional Indian remedies, chest rubs, and balms applied to neonates
• Ciprofloxacin: Rarely used in neonates but maternal use can affect breastfed infants
• High-dose vitamin C: Megadose supplementation can be oxidative

Safe Drugs for G6PD-Deficient Neonates

• Vitamin K (standard prophylactic dose): 1 mg IM at birth—SAFE and essential
• Paracetamol (acetaminophen): Safe for pain and fever
• Ampicillin, gentamicin: First-line NICU antibiotics—safe
• Cephalosporins: Generally safe
• Ibuprofen: Used for PDA closure—safe at standard doses

Management of G6PD-Related Neonatal Jaundice

Acute Management Protocol

1. Identify and remove the trigger: Stop the offending drug; remove naphthalene/camphor from the environment
2. Assess severity: Urgent TSB, hemoglobin, reticulocyte count, peripheral smear (Heinz bodies, bite cells), direct Coombs test (negative in G6PD hemolysis)
3. Intensive phototherapy: Start immediately for any significant jaundice—LED phototherapy with irradiance greater than 30 mcW/cm²/nm is recommended. HEAMAC phototherapy rental provides rapid access to high-quality LED units
4. Monitor bilirubin trajectory: TSB every 4-6 hours; G6PD hemolysis can cause rapid rises of 0.5-1 mg/dL/hour
5. Consider IVIG: If hemolysis is severe with rapidly rising TSB despite intensive phototherapy
6. Exchange transfusion readiness: Prepare for exchange if TSB approaches age-specific threshold; G6PD-deficient neonates use the lower (high-risk) threshold on AAP and NNF nomograms
7. Supportive care: IV fluids, maintain normothermia, correct acidosis if present

Lower Exchange Transfusion Thresholds

Both AAP and NNF classify G6PD deficiency as a "neurotoxicity risk factor" that lowers the treatment threshold:

Gestational Age	Standard Threshold (mg/dL)	With G6PD Risk (mg/dL)
≥38 weeks	25	20-22
35-37 weeks	20-22	18-20
Less than 35 weeks	Based on birth weight	Use lower nomogram line

Screening and Diagnosis

When to Test for G6PD Deficiency

• All male neonates with unexplained significant jaundice (TSB greater than 95th percentile for age)
• Jaundice with evidence of hemolysis (falling Hb, elevated reticulocytes, negative DAT)
• Family history of G6PD deficiency, favism, or hemolytic episodes
• Neonates from high-prevalence communities (tribal, Parsee, Gujarati, Rajasthani)
• Severe jaundice with no identified cause after standard workup

Diagnostic Methods Available in India

Test	Method	Turnaround	Cost (INR)	Availability
Fluorescent spot test	NADPH fluorescence	30-60 minutes	100-200	Most labs
Quantitative G6PD assay	Spectrophotometric	2-4 hours	300-600	Tertiary centers
Rapid point-of-care test	Biosensor/lateral flow	5-10 minutes	150-300	Increasing availability
Genetic testing	DNA mutation analysis	1-2 weeks	3,000-8,000	Reference labs only

Parental Education and Long-Term Management

Essential Discharge Counselling

Parental education is the single most important intervention for preventing future hemolytic episodes in G6PD-deficient neonates. Before discharge, parents must receive:

• A written drug avoidance card listing unsafe medications and substances in the local language
• Instructions to remove naphthalene mothballs from the home and use alternative pest deterrents
• Warning about menthol, camphor, henna application on the baby's skin
• Instruction to inform all healthcare providers about G6PD status before any medication is prescribed
• Information about the genetic inheritance pattern (X-linked) and implications for future pregnancies

Government Health System Integration

Given the high prevalence of G6PD deficiency in India, integration into public health programs is essential. The NNF has advocated for including G6PD screening in the Rashtriya Bal Swasthya Karyakram (RBSK) newborn screening program. Point-of-care rapid tests costing INR 150-300 make universal screening feasible even in resource-limited settings.

Clinical Pearl: G6PD deficiency should be suspected in any male neonate with severe jaundice that appears to be "out of proportion" to the clinical situation—particularly when DAT is negative, the blood group is compatible, and there is no apparent infection. A simple fluorescent spot test can confirm the diagnosis within an hour and fundamentally change the management approach including avoidance of oxidant drugs for life.